These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

319 related items for PubMed ID: 7989942

  • 1. Dose-ranging study of recombinant human granulocyte-macrophage colony-stimulating factor in small-cell lung carcinoma.
    Hamm J, Schiller JH, Cuffie C, Oken M, Fisher RI, Shepherd F, Kaiser G.
    J Clin Oncol; 1994 Dec; 12(12):2667-76. PubMed ID: 7989942
    [Abstract] [Full Text] [Related]

  • 2. Dose-intensity of a four-drug chemotherapy regimen with or without recombinant human granulocyte-macrophage colony-stimulating factor in extensive-stage small-cell lung cancer: a multicenter randomized phase III study.
    Pujol JL, Douillard JY, Rivière A, Quoix E, Lagrange JL, Berthaud P, Bardonnet-Comte M, Polin V, Gautier V, Milleron B, Chomy F, Chomy P, Spaeth D, Le Chevalier T.
    J Clin Oncol; 1997 May; 15(5):2082-9. PubMed ID: 9164221
    [Abstract] [Full Text] [Related]

  • 3. Chemoradiotherapy with or without granulocyte-macrophage colony-stimulating factor in the treatment of limited-stage small-cell lung cancer: a prospective phase III randomized study of the Southwest Oncology Group.
    Bunn PA, Crowley J, Kelly K, Hazuka MB, Beasley K, Upchurch C, Livingston R, Weiss GR, Hicks WJ, Gandara DR.
    J Clin Oncol; 1995 Jul; 13(7):1632-41. PubMed ID: 7602352
    [Abstract] [Full Text] [Related]

  • 4. Recombinant human granulocyte-macrophage colony-stimulating factor as an adjunct to conventional-dose ifosfamide-based chemotherapy for patients with advanced or relapsed germ cell tumors: a randomized trial.
    Bajorin DF, Nichols CR, Schmoll HJ, Kantoff PW, Bokemeyer C, Demetri GD, Einhorn LH, Bosl GJ.
    J Clin Oncol; 1995 Jan; 13(1):79-86. PubMed ID: 7799046
    [Abstract] [Full Text] [Related]

  • 5. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer.
    Crawford J, Ozer H, Stoller R, Johnson D, Lyman G, Tabbara I, Kris M, Grous J, Picozzi V, Rausch G.
    N Engl J Med; 1991 Jul 18; 325(3):164-70. PubMed ID: 1711156
    [Abstract] [Full Text] [Related]

  • 6. [Clinical study of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced leukopenia].
    Shi YK, Sun Y, Su M.
    Zhonghua Zhong Liu Za Zhi; 1994 Sep 18; 16(5):356-9. PubMed ID: 7895587
    [Abstract] [Full Text] [Related]

  • 7. Effect of rhGM-CSF on haematopoietic reconstitution after chemotherapy in small-cell lung cancer.
    Havemann K, Klausmann M, Wolf M, Fischer JR, Drings P, Oster W.
    J Cancer Res Clin Oncol; 1991 Sep 18; 117 Suppl 4():S203-7. PubMed ID: 1665493
    [Abstract] [Full Text] [Related]

  • 8. Can cytotoxic dose-intensity be increased by using granulocyte colony-stimulating factor? A randomized controlled trial of lenograstim in small-cell lung cancer.
    Woll PJ, Hodgetts J, Lomax L, Bildet F, Cour-Chabernaud V, Thatcher N.
    J Clin Oncol; 1995 Mar 18; 13(3):652-9. PubMed ID: 7533825
    [Abstract] [Full Text] [Related]

  • 9. Effect of recombinant human granulocyte-macrophage colony-stimulating factor in patients with Hodgkin's disease: a phase I/II study.
    Hovgaard DJ, Nissen NI.
    J Clin Oncol; 1992 Mar 18; 10(3):390-7. PubMed ID: 1740678
    [Abstract] [Full Text] [Related]

  • 10. Recombinant human granulocyte-macrophage colony-stimulating factor after combined chemotherapy in high-grade non-Hodgkin's lymphoma--a randomised pilot study.
    Bergmann L, Karakas T, Knuth A, Lautenschläger G, Mitrou PS, Hoelzer D.
    Eur J Cancer; 1995 Dec 18; 31A(13-14):2164-8. PubMed ID: 8652236
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Phase III study of intensive weekly chemotherapy with recombinant human granulocyte colony-stimulating factor versus standard chemotherapy in extensive-disease small-cell lung cancer. The Japan Clinical Oncology Group.
    Furuse K, Fukuoka M, Nishiwaki Y, Kurita Y, Watanabe K, Noda K, Ariyoshi Y, Tamura T, Saijo N.
    J Clin Oncol; 1998 Jun 18; 16(6):2126-32. PubMed ID: 9626212
    [Abstract] [Full Text] [Related]

  • 14. Randomized double-blind prospective trial to evaluate the effects of sargramostim versus placebo in a moderate-dose fluorouracil, doxorubicin, and cyclophosphamide adjuvant chemotherapy program for stage II and III breast cancer.
    Jones SE, Schottstaedt MW, Duncan LA, Kirby RL, Good RH, Mennel RG, George TK, Snyder DA, Watkins DL, Denham CA, Hoyes FA, Rubin AS.
    J Clin Oncol; 1996 Nov 18; 14(11):2976-83. PubMed ID: 8918495
    [Abstract] [Full Text] [Related]

  • 15. Tolerability and efficacy of GM-CSF [Leucomax] in patients with small cell lung cancer treated with intensive chemotherapy.
    Walewski J, Romejko-Jarosińska J, Zwoliński J, Falkowski S, Siedlecki P.
    Med Oncol; 1996 Dec 18; 13(4):199-205. PubMed ID: 9152970
    [Abstract] [Full Text] [Related]

  • 16. Clinical and virologic effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients receiving chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma: results of a randomized trial.
    Kaplan LD, Kahn JO, Crowe S, Northfelt D, Neville P, Grossberg H, Abrams DI, Tracey J, Mills J, Volberding PA.
    J Clin Oncol; 1991 Jun 18; 9(6):929-40. PubMed ID: 2033429
    [Abstract] [Full Text] [Related]

  • 17. Improving survival without reducing quality of life in small-cell lung cancer patients by increasing the dose-intensity of chemotherapy with granulocyte colony-stimulating factor support: results of a British Medical Research Council Multicenter Randomized Trial. Medical Research Council Lung Cancer Working Party.
    Thatcher N, Girling DJ, Hopwood P, Sambrook RJ, Qian W, Stephens RJ.
    J Clin Oncol; 2000 Jan 18; 18(2):395-404. PubMed ID: 10637255
    [Abstract] [Full Text] [Related]

  • 18. Recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) after chemotherapy in patients with non-Hodgkin's lymphoma; a placebo-controlled double blind phase III trial.
    Kaku K, Takahashi M, Moriyama Y, Nakahata T, Masaoka T, Yoshida Y, Shibata A, Kaneko T, Miwa S.
    Leuk Lymphoma; 1993 Oct 18; 11(3-4):229-38. PubMed ID: 8260897
    [Abstract] [Full Text] [Related]

  • 19. Bone marrow myeloid cell kinetics during treatment of small cell carcinoma of the lung with chemotherapy not associated and associated with granulocyte-macrophage colony-stimulating factor.
    Riccardi A, Danova M, Paccagnella A, Giordano M, Favaretto A, Panozzo M, Ghiotto C, Comis S, Fiorentino M, Chieco-Bianchi L.
    Ann Hematol; 1993 Apr 18; 66(4):185-93. PubMed ID: 8387346
    [Abstract] [Full Text] [Related]

  • 20. Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: an Eastern Cooperative Oncology Group Trial.
    Schiller JH, Kim K, Hutson P, DeVore R, Glick J, Stewart J, Johnson D.
    J Clin Oncol; 1996 Aug 18; 14(8):2345-52. PubMed ID: 8708727
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.